Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases

被引:0
|
作者
Koji Habe
Hideo Wada
Takeshi Matsumoto
Kohshi Ohishi
Makoto Ikejiri
Kimiko Matsubara
Tatsuhiko Morioka
Yuki Kamimoto
Tomoaki Ikeda
Naoyuki Katayama
Tsutomu Nobori
Hitoshi Mizutani
机构
[1] Mie University Graduate School of Medicine,Department of Dermatology
[2] Mie University Graduate School of Medicine,Department of Molecular and Laboratory Medicine
[3] Mie University Graduate School of Medicine,Department of Blood Transfusion
[4] Mie University Graduate School of Medicine,Department of Obstetrics and Gynecology
[5] Mie University Graduate School of Medicine,Department of Hematology and Oncology
来源
关键词
APS; Thrombosis; aPL; LA; β2-Glycoprotein I;
D O I
暂无
中图分类号
学科分类号
摘要
Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.
引用
收藏
页码:345 / 350
页数:5
相关论文
共 50 条
  • [21] The Antiphospholipid Syndrome - Important Cause of Thrombotic Events in Pregnancy
    Dumitrascu, A.
    Draghici, C.
    Tamsula, I.
    Popescu, M.
    Dumitrascu, C.
    Tanaseanu, C.
    PROCEEDINGS OF THE 20TH INTERNATIONAL CONGRESS ON THROMBOSIS, 2008, : 123 - 128
  • [22] Thromboembolic neurologic events in patients with antiphospholipid-antibody syndrome
    Turazzini, M
    Giavarina, D
    Del Colle, R
    Zamperetti, M
    Schiavon, R
    Silvestri, M
    ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 20 (01): : 71 - 72
  • [23] Thromboembolic neurologic events in patients with antiphospholipid-antibody syndrome
    M. Turazzini
    D. Giavarina
    R. Del Colle
    M. Zamperetti
    R. Schiavon
    M. Silvestri
    The Italian Journal of Neurological Sciences, 1999, 20 : 71 - 72
  • [24] Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome
    Crowther, MA
    THROMBOSIS RESEARCH, 2004, 114 (5-6) : 443 - 446
  • [25] The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics
    Marta Tonello
    Antonia Calligaro
    Maria Favaro
    Teresa Del Ross
    Paola Veronese
    Elisa Salvan
    Maria Teresa Gervasi
    Amelia Ruffatti
    Archives of Gynecology and Obstetrics, 2021, 303 : 455 - 461
  • [26] The presence of additional thrombophilic risk factors is strongly associated with thrombotic events in patients with Antiphospholipid antibodies.
    Miesbach, W
    Boehm, M
    Asmelash, G
    Scharrer, I
    BLOOD, 2003, 102 (11) : 115B - 115B
  • [27] The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics
    Tonello, Marta
    Calligaro, Antonia
    Favaro, Maria
    Del Ross, Teresa
    Veronese, Paola
    Salvan, Elisa
    Gervasi, Maria Teresa
    Ruffatti, Amelia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (02) : 455 - 461
  • [28] Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study
    Mustonen, P.
    Lehtonen, K. V.
    Javela, K.
    Puurunen, M.
    LUPUS, 2014, 23 (14) : 1468 - 1476
  • [29] Thrombotic Risk Factors, Antithrombotic Therapy, and Outcomes of Asymptomatic Carriers of Antiphospholipid Antibodies and Patients with Antiphospholipid Syndrome
    Abu-Zeinah, Ghaith
    Oromendia, Clara
    De Sancho, Maria Teresa
    BLOOD, 2017, 130
  • [30] The risk of overdiagnosis of antiphospholipid antibody syndrome
    Pengo, V
    Biasiolo, A
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (03) : 933 - 933